newsfilter
← Latest News
Business Wire·

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

  • TibuSHIELD Phase 2 data in hidradenitis suppurativa is on track for Q4 2026 after completing enrollment of 247 participants.
  • TibuSURE Phase 2 data in systemic sclerosis is on track for H1 2027 after completing enrollment of 91 participants.
  • The NEXUS-PMR Phase 2 study for tibulizumab in polymyalgia rheumatica is FDA-cleared \& expected to initiate by year-end 2026.
  • Zura reported $187.7 million in cash \& cash equivalents as of September 30, 2026, sufficient to fund operations through at least the end of 2028.
  • Third-quarter 2026 research \& development expenses were $19.5 million, an increase from $11.9 million in the same period of 2025.
  • Third-quarter 2026 general \& administrative expenses were $9.3 million, an increase from $7.6 million in the same period of 2025.
  • The net loss for the third quarter of 2026 was $25.8 million, or $0.20 per share, compared to $20.0 million, or $0.21 per share, in 2025.
  • Tibulizumab is an investigational bispecific antibody targeting IL-17 \& BAFF with no regulatory approval granted.
  • Zura continues evaluating torudokimab (ZB-880) \& crebankitug (ZB-168) based on Phase 1/1b data.